Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma.

Find more on Medicine Matters oncology

This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on May 4, 2018.